Biogen entered a definitive agreement to acquire RayThera, a private biotechnology company focused on small molecule immunology therapies, for up to $1 billion.

The deal expands Biogen’s immunology pipeline with a new class of assets as it simultaneously advances its own late-stage biologics programs in the same space.

What does RayThera bring to Biogen?

RayThera's portfolio consists of multiple anti-inflammatory small molecule candidates targeting immune-mediated conditions across a range of indications.¹ The company has not disclosed specific disease targets or mechanisms of action for its programs, but has positioned the assets as having broad potential across immunology. The lead candidate is expected to enter Phase I clinical development in early Q3 2026, aligning closely with the anticipated deal close which enables Biogen to move quickly into the clinic once the acquisition is finalized.¹

"With this acquisition, we are further deepening our pipeline in immunology by adding a suite of assets that can allow us to expand into new disease areas," said Priya Singhal, MD, MPH, executive vice president and head of development at Biogen. "We believe these assets can meaningfully contribute to our long-term pipeline potential and we're excited about the opportunity to rapidly advance the first candidate into the clinic."

What are the details of the agreement?

Under the terms of the agreement, Biogen is set to make an upfront payment to RayThera's shareholders, who will also be eligible for clinical and regulatory milestone payments. The total potential deal value is up to $1 billion, with the majority tied to future milestones rather than paid upfront.¹ The transaction is expected to close in the third quarter of 2026 and is subject to customary regulatory approvals. Upon close, Biogen will lead development, manufacturing, and global commercialization of RayThera's assets.¹

Why is this deal strategically significant for Biogen?

The acquisition comes as Biogen is already advancing a late-stage immunology program in its existing pipeline. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled Phase III study evaluating litifilimab (BIIB059), a biologic, in adults with active systemic lupus erythematosus receiving background standard-of-care therapy.² The trial, which assesses litifilimab across 52 weeks of treatment using validated disease activity measures including the SLE Responder Index and BICLA, represents Biogen's most advanced immunology program and reflects a significant existing commitment to the space.²

"With its strong global development capabilities in immunology, we believe that Biogen is the natural fit to move these assets forward into Phase I development and beyond," said Qing Dong, co-founder, chairman, and CEO of RayThera. "I am proud of our team at RayThera for the innovative pipeline we have built together and the rapid advancement of these molecules."

The milestone-heavy deal structure limits Biogen's near-term financial exposure while preserving potential upside for RayThera shareholders if the programs advance.¹ It also signals Biogen's confidence in it’s exsisting pipeline along with enabling the company to manage capital discipline as it continues to invest across its neuroscience and rare disease franchises in parallel.¹

For RayThera, the transaction provides immediate access to Biogen's global development infrastructure, regulatory expertise, and commercial reach, a pathway that would be difficult to replicate independently for a private biotechnology company at the pre-clinical and early clinical stage.

Sources

1. Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Biogen June 17, 2026 https://www.globenewswire.com/news-release/2026/06/17/3313870/0/en/biogen-expands-immunology-pipeline-with-agreement-to-acquire-raythera-inc.html
2. A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2) National Library of Medicine January 29, 2026 https://clinicaltrials.gov/study/NCT04961567